

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2021**

NQF#	PCH#	Measures Grouped by Measure Topic	Program Year					
			FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021
Clinical Process/Cancer-Specific Treatment								
#0223	PCH-1	Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer	✓	✓	✓	N/A	N/A	N/A
#0559	PCH-2	Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1cN0M0, or Stage IB—III Hormone Receptor Negative Breast Cancer	✓	✓	✓	N/A	N/A	N/A
#0220	PCH-3	Adjuvant Hormonal Therapy	✓	✓	✓	N/A	N/A	N/A
Safety and Healthcare-Associated Infection								
#0139	PCH-4	NHSN Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure	✓	✓	✓	✓	✓	✓
#0138	PCH-5	NHSN Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure	✓	✓	✓	✓	✓	✓
#0753	PCH-6* PCH-7*	ACS–CDC Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure	✓§	✓	✓	✓	✓	✓
#1717	PCH-26	NHSN Facility-wide Inpatient Hospital-onset <i>Clostridium difficile</i> Infection (CDI) Outcome Measure	N/A	N/A	✓	✓	✓	✓
#1716	PCH-27	NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) Bacteremia Outcome Measure	N/A	N/A	✓	✓	✓	✓

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2021**

NQF#	PCH#	Measures Grouped by Measure Topic	Program Year					
			FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021
#0431	PCH-28	NHSN Influenza Vaccination Coverage Among Healthcare Personnel (HCP)	N/A	N/A	✓	✓	✓	✓
Clinical Process/Oncology Care Measures								
#0382	PCH-14 ^{wp}	Oncology: Radiation Dose Limits to Normal Tissues	✓†	✓§	✓	✓	✓	N/A
#0383	PCH-15	Oncology: Plan of Care for Pain—Medical Oncology and Radiation Oncology (paired with 0384)	✓†	✓§	✓	✓	✓	✓
#0384	PCH-16 ^{wp}	Oncology: Medical and Radiation—Pain Intensity Quantified	✓†	✓§	✓	✓	✓	N/A
#0390	PCH-17 ^{wp}	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	✓†	✓§	✓	✓	✓	N/A
#0389	PCH-18 ^{wp}	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	✓†	✓§	✓	✓	✓	N/A
#0210	PCH-32	Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life	N/A	N/A	N/A	N/A	✓	✓
#0215	PCH-34	Proportion of Patients Who Died from Cancer Not Admitted to Hospice	N/A	N/A	N/A	N/A	✓	✓
Intermediate Clinical Outcome Measures								
#0213	PCH-33	Proportion of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life	N/A	N/A	N/A	N/A	✓	✓
#0216	PCH-35	Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than Three Days	N/A	N/A	N/A	N/A	✓	✓

**PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2021**

NQF#	PCH#	Measures Grouped by Measure Topic	Program Year					
			FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021
Surgical Care Improvement Project (SCIP)								
#0218	PCH-19	SCIP-VTE-2 Surgery Patients Who Received Appropriate Venous Thromboembolism Prophylaxis Within 24 Hours Prior to Surgery to 24 Hours After Surgery	✓†	✓‡	N/A	N/A	N/A	N/A
#0453	PCH-20	SCIP-Inf-9 Urinary Catheter Removed on Postoperative Day 1 (POD1) or Postoperative Day 2 (POD2) with Day of Surgery Being Day Zero	✓†	✓‡	N/A	N/A	N/A	N/A
#0527	PCH-21	SCIP-Inf-1 Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision	✓†	✓‡	N/A	N/A	N/A	N/A
#0528	PCH-22	SCIP-Inf-2 Prophylactic Antibiotic Selection for Surgical Patients	✓†	✓‡	N/A	N/A	N/A	N/A
#0529	PCH-23	SCIP-Inf-3 Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time	✓†	✓‡	N/A	N/A	N/A	N/A
#0284	PCH-24	SCIP-Card-2 Surgery Patients on Beta-Blocker Therapy Prior to Arrival Who Received a Beta-Blocker During the Perioperative Period	✓†	✓‡	N/A	N/A	N/A	N/A
Clinical Effectiveness Measure								
N/A	PCH-25	External Beam Radiotherapy for Bone Metastases	N/A	✓	✓	✓	✓	✓
Patient Engagement/Experience of Care								
#0166	PCH-29	Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey	✓§	✓	✓	✓	✓	✓

PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Measure Crosswalk by Measure Type for Program Years FY 2016 to FY 2021

NQF#	PCH#	Measures Grouped by Measure Topic	Program Year					
			FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021
Claims-Based Outcome Measure								
N/A	PCH-30[†] PCH-31[‡]	Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy	N/A	N/A	N/A	✓	✓	✓
#3188	N/A	30-Day Unplanned Readmissions for Cancer Patients	N/A	N/A	N/A	N/A	N/A	✓

NOTE: ✓=Applicable for stated program year; AJCC=Adjuvant Chemotherapy Considered; N/A=Not applicable for stated program year; FY=Fiscal Year; NQF=National Quality Forum; NHSN=National Healthcare Safety Network; ACS-CDC=American College of Surgeons—Centers for Disease Control and Prevention

* While NQF #0753 is a single harmonized measure containing SSI data for both colon and abdominal hysterectomies, the data are reported specific to each surgery on the PPS-Exempt Cancer Hospital Report; therefore, it has two PCH numbers, PCH-6 (SSI-colon) and PCH-7 (SSI-hysterectomy). § Quarters 2–4 apply to the Fiscal Year.

[¶] Measure finalized for removal from the PCHQR Program in the FY 2019 IPPS/LTCH PPS Final Rule, beginning FY 2021 Program Year and subsequent years.

† Only Quarter 1 applies to Fiscal Year 2016.

‡ Only Quarters 2 and 3 apply to this Fiscal Year.

[§] While PCH-30 and PCH-31 are part of a single measure, Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy, there are two rates reported. PCH-30 is the risk-standardized admission rate (RSAR), and PCH-31 is the risk-standardized ED visit rate (RSEDR).